- Home
- FWRG vs MLTX Comparison
FWRG vs MLTX Comparison
Compare FWRG & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$11.70
N/A
Current Price
$17.02
Company Overview
Basic Information| Metric | FWRG | MLTX |
|---|---|---|
| Founded | 1983 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 975.9M | 1.1B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FWRG | MLTX |
|---|---|---|
| Price | $11.70 | $17.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | $20.64 | ★ $29.73 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 05-15-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.33 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,222,501,000.00 | N/A |
| Revenue This Year | $15.58 | N/A |
| Revenue Next Year | $12.67 | N/A |
| P/E Ratio | $40.13 | ★ N/A |
| Revenue Growth | ★ 20.34 | N/A |
| 52 Week Low | $11.88 | $5.95 |
| 52 Week High | $19.84 | $62.75 |
Technical Indicators
Market Signals| Indicator | FWRG | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.10 | 48.01 |
| Support Level | N/A | $17.00 |
| Resistance Level | $18.56 | $19.15 |
| Average True Range (ATR) | 0.80 | 0.84 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 1.04 | 5.16 |
Price Performance
Historical Comparison FWRG
MLTX
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.